{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:13:52Z","timestamp":1737695632282,"version":"3.33.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-024-01661-y","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:51:01Z","timestamp":1737618661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan"],"prefix":"10.1186","volume":"25","author":[{"given":"Hui-Lei","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mau-Shin","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ling","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Dar","family":"Juang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas I-Sheng","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan-Hwa","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"3","key":"1661_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1661_CR2","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary J-P, et al. Effect of Standard vs dose-escalated Radiation Therapy for patients with intermediate-risk prostate Cancer: the NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018;4(6):e180039\u2013e.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1661_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","volume":"110","author":"WD Heemsbergen","year":"2014","unstructured":"Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104\u20139.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1661_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","volume":"104","author":"D Pasalic","year":"2019","unstructured":"Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019;104(4):790\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1661_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","volume":"52","author":"DJ Brenner","year":"2002","unstructured":"Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52(1):6\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1661_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","volume":"50","author":"J Fowler","year":"2001","unstructured":"Fowler J, Chappell R, Ritter M. Is alpha\/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50(4):1021\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1661_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360.","journal-title":"Lancet Oncol"},{"issue":"17","key":"1661_CR8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the treatment of localized prostate Cancer. J Clin Oncol. 2017;35(17):1884\u201390.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1661_CR9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in patients with low-risk prostate Cancer. J Clin Oncol. 2016;34(20):2325\u201332.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1661_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061\u20139.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1661_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2174\/1574887116666210509004418","volume":"16","author":"A Kougioumtzopoulou","year":"2021","unstructured":"Kougioumtzopoulou A, Platoni K, Zygogianni A, Kounadis G, Syrigos KN, Psyrri A, et al. Moderate Hypofractionated Radiotherapy for localized prostate Cancer: the triumph of Radiobiology. Rev Recent Clin Trials. 2021;16(4):351\u201371.","journal-title":"Rev Recent Clin Trials"},{"issue":"4","key":"1661_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464\u201374.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1661_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/1008-682X.132780","volume":"17","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Wang HK, Qu YY, Ye DW. Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl. 2015;17(1):48\u201357.","journal-title":"Asian J Androl"},{"key":"1661_CR14","doi-asserted-by":"crossref","unstructured":"Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28(1):33\u20137.","DOI":"10.1016\/0360-3016(94)90138-4"},{"issue":"17","key":"1661_CR15","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","volume":"35","author":"G Arcangeli","year":"2017","unstructured":"Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, Strigari L. Moderate hypofractionation in High-Risk, organ-confined prostate Cancer: final results of a phase III Randomized Trial. J Clin Oncol. 2017;35(17):1891\u20137.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1661_CR16","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1661_CR17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","volume":"68","author":"PA Kupelian","year":"2007","unstructured":"Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1661_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","volume":"113","author":"GA Viani","year":"2022","unstructured":"Viani GA, Gouveia AG, Moraes FY, Cury FL. Meta-analysis of Elective Pelvic nodal irradiation using moderate hypofractionation for high-risk prostate Cancer. Int J Radiat Oncol Biol Phys. 2022;113(5):1044\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1661_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","volume":"2","author":"ND James","year":"2016","unstructured":"James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate Cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol. 2016;2(3):348\u201357.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1661_CR20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","volume":"23","author":"CA Lawton","year":"2005","unstructured":"Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85\u2009\u2013\u200931. J Clin Oncol. 2005;23(4):800\u20137.","journal-title":"J Clin Oncol"},{"key":"1661_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers13153868","volume":"13","author":"M Onishi","year":"2021","unstructured":"Onishi M, Kawamura H, Murata K, Inoue T, Murata H, Takakusagi Y, et al. Intensity-modulated Radiation Therapy with Simultaneous Integrated Boost for clinically node-positive prostate Cancer: a single-institutional retrospective study. Cancers (Basel). 2021;13:15.","journal-title":"Cancers (Basel)"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01661-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:51:07Z","timestamp":1737618667000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01661-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01661-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Shin Kong Wu Ho-Su Memorial Hospital (reference number 20230806R), and informed consent was obtained from all patients before treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as the data were analyzed in anonymized form and did not contain data from any individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}